Drugs Education Prevention and Policy
March 22, 2026
Jordan J. Negrine, Stephen Bright, Monica J Barratt et al.
Background Following Australia’s landmark 2023 decision to approve psilocybin and MDMA for clinical use, psychedelic-assisted therapy (PAT) is beginning to emerge within regulated mental health settings. This study investigates psychologists’ views on the relevance of psychedelic therapists’ lived-living experience (LLE) with psychedelics. While discussion around LLE is growing, little is known...
Drugs Education Prevention and Policy
October 14, 2024
Felipe Krause
2 citations
Background In the early twentieth century, ayahuasca gained popularity in northern Brazil, causing political tension due to moral hostility. However, over the course of the century, despite the proscription of DMT and the intensification of the ‘War on Drugs’, three phases of cumulative political gains eventually led to the full regulation of ayahuasca, in 2010. How was this achieved?Methods...
Drugs Education Prevention and Policy
October 9, 2024
Jesper Dunell
2 citations
Background Currently, there are great hopes for psychedelic substances in treating psychiatric conditions and improving well-being. These substances are illegal in many countries, and we lack knowledge of how conflicting discourses shape psychedelic use in naturalistic settings. This study explores how psilocybin use is made meaningful by participants and staff at a retreat including...
Drugs Education Prevention and Policy
June 4, 2024
Eli Kraiem, Marc J. Diener, Jeffrey Guss et al.
4 citations
Background Numerous clinical trials have supported psychedelic-assisted therapy (PAT) as a treatment for psychiatric disorders such as depression, anxiety, post-traumatic stress, and substance use. While empirical evidence indicates PAT’s benefits, the perspectives of mental health practitioners on this topic remain unclear.Methods This quantitative study attempted to capture psychoanalyst...
Drugs Education Prevention and Policy
October 30, 2023
Henry Harder, Fabian P. Steinmetz, Maja Kohek
3 citations
Background The global drug control landscape is undergoing remarkable change. Many jurisdictions around the world, including jurisdictions in the United States, have decriminalized the possession and use of plant- and fungus-based psychedelics, such as psilocybin-containing mushrooms (PCM). With ORS 475 A, Oregon has gone a step further by becoming the first US state to legalize and regulate...
Drugs Education Prevention and Policy
September 4, 2022
Jason B. Luoma, Brian Pilecki, Alan K. Davis et al.
13 citations
As evidence for psychedelic-assisted therapy accumulates, legalization becomes more likely. As a result, there is an increasing need for psychologists to become educated about psychedelics and their therapeutic effects as they will play an important role in disseminating this treatment. Therefore, understanding psychologists’ current attitudes toward psychedelics is integral in informing...
Drugs Education Prevention and Policy
April 30, 2021
Johannes Thrul, Albert Garcia‐romeu
78 citations
Growing research on potential therapeutic applications of highly restricted Schedule I hallucinogens, including the ‘classic psychedelic’ psilocybin, and the entactogen 3,4-Methylenedioxymethamphet...
Drugs Education Prevention and Policy
December 10, 2020
Monnica T. Williams, Alan K. Davis, Yitong Xin et al.
100 citations
This study examined how psychedelics reduced symptoms of racial trauma among black, indigenous, and people of color (BIPOC) subsequent to an experience of racism. A cross-sectional internet-based survey included questions about experiences with racism, mental health symptoms, and acute and enduring psychedelic effects. Changes in mental health were assessed by retrospective report of symptoms...
Drugs Education Prevention and Policy
September 10, 2020
Jan Van Amsterdam, Johannes G. Ramaekers, Ton Nabben et al.
4 citations
Introduction Ecstasy (MDMA) is a popular recreational drug, but its illegal production and trade in the Netherlands have developed into a serious public order and ecological problem which endanger and question the harm reduction approach of the Dutch ecstasy policy.Methods The market characteristics, adverse health effects, risk profile, and link to criminal activity of ecstasy were...
Drugs Education Prevention and Policy
May 7, 2019
Marc Aixalà, Genís Ona, Òscar Parés et al.
16 citations
In recent years, the use of natural psychoactive drugs (NPDs) has grown rapidly. They are classified as new psychoactive substances (NPSs), despite the reality that they have been used for centuries. We are lacking information regarding patterns of use or characteristics of users, but some evidence suggests that NPDs substantially differ from NPSs in terms of both their safety profile and...
Drugs Education Prevention and Policy
July 16, 2013
Judith Aldridge
1 citation
The internationalisation of the ayahuasca phenomenon provides those with an interest in drug use, supply and policy with a fascinating opportunity to reflect critically on the state of contemporary...
Drugs Education Prevention and Policy
August 25, 2011
Beatriz Caiuby Labate
14 citations
This article comments on the agreement signed in 2010 between a US branch of the Brazilian ayahuasca religion União do Vegetal (UDV) and the US Drug Enforcement Agency. This document settles a dispute regarding administrative issues involving ayahuasca, a psychoactive brew used by this group as a religious sacrament. The government originally confiscated this substance in 1999, and the matter...
Drugs Education Prevention and Policy
June 1, 2004
Sarah Riley, Emma Hayward
52 citations
A survey of drug use in the past year was completed by 124 clubbers (50% male, 50% female, age range 14–44, mean 24 years). Participants were self selecting and recruited in clubs and pre-club bars. Prevalence rates for alcohol, cannabis, and ecstasy were over 80%; 63% reported cocaine and 53% amphetamine use, 15%–43% used ketamine, psilocybin, LSD and nitrites. A pattern of polydrug and...